Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to 102 weeks, plus sham photodynamic therapy (PDT) to Macugen plus PDT with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD).

Next Previous
X
Search
Trial Profile

A Phase 3B/4, randomized, active controlled, double-masked, single dummy, multi-center comparative trial, in parallel groups, to compare the safety and efficacy of intravitreous injections of Macugen given every 6 weeks for up to 102 weeks, plus sham photodynamic therapy (PDT) to Macugen plus PDT with Visudyne in subjects with predominantly classic subfoveal choroidal neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD).

Status: Completed
Phase of Trial: Phase III/IV

Latest Information Update: 02 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegaptanib (Primary) ; Verteporfin
  • Indications Age-related macular degeneration; Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Therapeutic Use
  • Sponsors Eyetech Pharmaceuticals

    • Most Recent Events

    • 12 Oct 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top